Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic vortioxetine 20 mg vs Brintellix in healthy Thai volunteers under fasting conditions
TCTR20250619007Phase 1Unknown
- Sponsor
- International Bio Service
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic bioequivalence parameters. Status: unknown.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on TCTR20250619007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250619007.